Advertisement
Advertisement

ASMB

ASMB logo

Assembly Biosciences, Inc

31.72
USD
Sponsored
+0.90
+2.92%
May 13, 16:00 UTC -4
Closed
exchange

After-Market

31.75

+0.03
+0.09%

Assembly Biosciences, Inc Profile

About

Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.

Info & Links

CEO

Jason A. Okazaki

Headquarters

TWO TOWER PLACE, 7TH FLOOR
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES

Industry

Medical Generic Drugs

Sector

Medical

Website

www.assemblybio.com

Auditor

Ernst & Young LLP

Share holders

56

Employees

73

Assembly Biosciences, Inc Statistics

Valuation Measures

Market Capitalization2

504.59M

Enterprise Value

446.14M

Enterprise Value/EBITDA(ttm)

-31.12

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

6.55

Price to Book(mrq)

2.29

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-8.47%

Profit Margin(ttm)

-58.20%

Return on Equity(ttm)

-5.63%

Return on Invested Capital(ttm)

-83.19%

Return on Assets(ttm)

-3.62%

Income Statement

Revenue(ttm)

72.30M

Revenue Per Share(ttm)

4.56

Gross Profit(ttm)

72.30M

EBITDA(ttm)3

-14.34M

Net Income Available to Common(ttm)

-6.12M

Diluted EPS(ttm)

-0.74

Share Statistics

Beta (5Y Monthly)

1.15

52-Week Change

156.84%

S&P 500 52-Week Change

26.46%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

15.86M

Dividend Yield

0.00%

Float4

15.02M

% Held by Insiders

5.30%

% Held by Institutions

19.92%

Balance Sheet

Total Cash(mrq)

248.11M

Total Cash Per Share(mrq)

15.64

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

5.22%

Quick Ratio(mrq)

5.22%

Book Value Per Share(mrq)

13.04

Cash Flow

Operating Cash Flow Per Share(ytd)

-3.67

Free Cash Flow(ytd)

-41.16M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement